Your browser doesn't support javascript.
loading
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.
Rejeski, Kai; Hansen, Doris K; Bansal, Radhika; Sesques, Pierre; Ailawadhi, Sikander; Logue, Jennifer M; Bräunlein, Eva; Cordas Dos Santos, David M; Freeman, Ciara L; Alsina, Melissa; Theurich, Sebastian; Wang, Yucai; Krackhardt, Angela M; Locke, Frederick L; Bachy, Emmanuel; Jain, Michael D; Lin, Yi; Subklewe, Marion.
Afiliación
  • Rejeski K; Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany. kai.rejeski@med.uni-muenchen.de.
  • Hansen DK; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. kai.rejeski@med.uni-muenchen.de.
  • Bansal R; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany. kai.rejeski@med.uni-muenchen.de.
  • Sesques P; Bavarian Cancer Research Center (BZKF), Munich partner site, Munich, Germany. kai.rejeski@med.uni-muenchen.de.
  • Ailawadhi S; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, USA.
  • Logue JM; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Bräunlein E; Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, Pierre-Bénite, France.
  • Cordas Dos Santos DM; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
  • Freeman CL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, USA.
  • Alsina M; IIIrd Medical Department, Klinikum rechts der Isar and Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany.
  • Theurich S; Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
  • Wang Y; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany.
  • Krackhardt AM; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, USA.
  • Locke FL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, USA.
  • Bachy E; Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
  • Jain MD; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany.
  • Lin Y; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Subklewe M; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany.
J Hematol Oncol ; 16(1): 88, 2023 07 31.
Article en En | MEDLINE | ID: mdl-37525244
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores Quiméricos de Antígenos / Mieloma Múltiple Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores Quiméricos de Antígenos / Mieloma Múltiple Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido